# A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

> **NCT02717611** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 60 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** ACP-196 (acalabrutinib)

## Key facts

- **NCT ID:** NCT02717611
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-03-08
- **Primary completion:** 2020-10-16
- **Final completion:** 2026-06-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02717611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02717611, "A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02717611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*